Showing 1 - 10 of 18
Persistent link: https://www.econbiz.de/10011120757
Persistent link: https://www.econbiz.de/10010825933
Normalization of expression levels applied to microarray data can help in reducing measurement error. Different methods, including cyclic loess, quantile normalization and median or mean normalization, have been utilized to normalize microarray data. Although there is considerable literature...
Persistent link: https://www.econbiz.de/10005585091
Maintenance genes can be used for normalization in the comparison of gene expressions. Even though the absolute expression levels of maintenance genes may vary considerably among different tissues or cells, a set of maintenance genes may provide suitable normalization if their expression levels...
Persistent link: https://www.econbiz.de/10005178552
Persistent link: https://www.econbiz.de/10008784003
We develop a real options model of R&D valuation that takes into account the uncertainty in the quality (or efficacy) of the research output, the time and cost to completion, and the market demand for the R&D output. The model is then applied to study the problem of pharmaceutical...
Persistent link: https://www.econbiz.de/10005374864
To control increasing pharmaceutical expenditures, Taiwan's National Health Insurance has implemented a series of drug reimbursement price reductions since 2000. This study examined changes in use and expenditures of oral antidiabetic medications following the price regulation in November 2006.
Persistent link: https://www.econbiz.de/10010776766
This paper produces endogenous equity market non-participation in an economy with uninsurable labor income risk and heterogeneous skill levels. Prudence and impatience generate stationary household wealth levels that depend on income. Skill, and therefore labor income, heterogeneity leads to...
Persistent link: https://www.econbiz.de/10010886096
Persistent link: https://www.econbiz.de/10010946597
We develop a real options model of R&D valuation, which takes into account the uncertainty in the quality of the research output, the time and cost to completion, and the market demand for the R&D output. The model is then applied to study the problem of pharmaceutical under-investment in R&D...
Persistent link: https://www.econbiz.de/10010535935